Backs FY25 revenue view up 9%-10%. Edwards Lifesciences (EW) will outline its strategy and share financial guidance during its annual investor conference.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Promising Outlook for Edwards Lifesciences: TAVR Expansion and Strong Growth Prospects Drive Buy Rating
- Cautious Optimism for Edwards Lifesciences Amid Growth Strategy Reassessment
- Edwards Lifesciences price target raised to $90 from $87 at Truist
- Edwards Lifesciences price target raised to $104 from $94 at Goldman Sachs
- Edwards Lifesciences price target raised to $90 from $85 at UBS